The use of inhibitors of angiogenesis in patients with inoperable locally advanced or metastatic renal cell cancer: guideline recommendations.
The use of inhibitors of angiogenesis in patients with inoperable locally advanced or metastatic renal cell cancer: guideline recommendations.
12th March 2010
Program in Evidence-based Care
To evaluate in adult patients with inoperable locally advanced or metastatic renal cell cancer (RCC) whether:
Program in Evidence-based Care
Source: National Guidelines Clearinghouse
DISEASE/CONDITION(S)
Inoperable locally advanced or metastatic renal cell cancer
GUIDELINE CATEGORY
- Assessment of Therapeutic Effectiveness
- Treatment
- Nephrology
- Oncology
- Pharmacology
- Urology
- Physicians
To evaluate in adult patients with inoperable locally advanced or metastatic renal cell cancer (RCC) whether:
- Treatment with inhibitors of angiogenesis improves overall (OS) and/or progression-free survival (PFS) and additional outcomes such as quality of life (QOL), objective tumour response rate, clinical response rate, and adverse effects
- A combination of inhibitors of angiogenesis are better than any single-agent angiogenesis inhibitor
- Sequential administration of a second inhibitor of angiogenesis offers additional benefit to patients
